The medical technologies evaluation programme (MTEP) at NICE produces guidance and advice on medical devices and diagnostic technologies.
It also facilitates important research on technologies where we have identified the need for it in our guidance. For example, the management of blood glucose levels in type 1 diabetes and tests to rule out heart attacks in women.
There are two parts to the programme:
We published a total of 38 MIBs covering a wide range of topics. Some examples include:
MIBs continue to grow in popularity both across the NHS and with technology manufacturers.
In 2016/17, the number of people viewing the MIB section of the NICE website doubled compared with 2015/16. We currently receive around 700 views per day.
We have also seen an increased interest in new MIB topics. With our web analytics showing more than double the level of visitor traffic compared to when our first MIBs published three years ago.
We published five new MTGs in 2016/17, bring our total number to 33.
Four of our new MTGs recommended that the technology or device be available for routine NHS use and one said that further evidence was needed.
In March 2017, proposals we put forward for further research on two of our existing MTGs were approved:
These proposals have attracted over £0.5 million in funding. The research is expected to be completed in September 2018 and June 2019 respectively. It is hoped the new data will be used to update the current guidance and provide the NHS with a definitive stance on whether these technologies should be adopted.
In February 2017, we produced guidance on new HeartFlow technology, which uses data collected from CT scans to assess how well blood flows through a patient’s heart.
HeartFlow generates a 3D model of the patient’s heart and then simulates blood flow to show how it may be affected by different conditions, such as thinning of the arteries.
This technology has been adopted by the NHS. Estimates suggest that it could save the NHS £214 per patient due to the avoidance of further invasive treatment.
In June 2016, we recommended the GreenLight XPS laser treatment system for patients who have benign enlarged prostate.
The NICE committee found that men benefit from a quicker return to normal activity following treatment with the Greenlight XPS laser. Their stay in hospital was also shortened due to the procedure taking less time than traditional surgery.